Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated radiotherapy + PD-1 inhibitor + GM-CSF + thymosin α1 in advanced metastatic solid tumors
ChiCTR2200062706Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Nonhematologic neoplasms, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Median progression-free survival. Started Aug 2022; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2200062706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062706.